drugset / Trial / NCT02248883

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

NCT02248883

Phase 1 Completed 81 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir

Timeline

Start
2005-12
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule
Subject Tipranavir Small molecule
Background Ritonavir Other / unclassified

Indications

No indication recorded.